Clinical trial · Interventional
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Randomized, Open-label, Multicenter, Phase III Clinical Study Comparing Rocbrutinib Monotherapy Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (PRIME Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that exhibits both covalent (irreversible) and non-covalent (reversible) binding. This unique dual mechanism of action has shown promising efficacy and a favorable safety profile across various B-cell NHL subtypes in prior Phase 1 and 2 studies. This is a Phase 3, randomized, open-label study comparing Rocbrutinib versus investigator's choice of BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or orelabrutinib) in patients with MCL who have received at least one prior line of therapy and are naïve to BTK inhibitor treatment (except for intolerance).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mantle Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acalabrutinib | Drug | Acalabrutinib | ALIAS |
| Ibrutinib | Drug | Ibrutinib | ALIAS |
| Orelabrutinib | Drug | — | UNRESOLVED |
| Rocbrutinib | Drug | — | UNRESOLVED |
| Zanubrutinib | Drug | Zanubrutinib | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm A (Rocbrutinib)
- interventionNames
- Drug: Rocbrutinib
- type
- ACTIVE_COMPARATOR
- label
- Arm B (ibrutinib, acalabrutinib, zanubrutinib, or orelabrutinib)
- interventionNames
- Drug: Ibrutinib
- Drug: Acalabrutinib
- Drug: Zanubrutinib
- Drug: Orelabrutinib
Primary outcomes (1)
- measure
- Progression-free survival (PFS) assessed by IRC
- timeFrame
- approximately 30 months
Secondary outcomes (6)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with MCL, who have received at least one prior systemic regimen(s), and have experienced disease progression on the most recent line of therapy. * Have at least one measurable lesion according to the Lugano Response Criteria 2014. * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2. * Life expectancy ≥ 12 weeks. * Adequate coagulation function, liver and kidney function, bone marrow hematopoietic function, etc. * Toxicities or complications from prior anti-tumor therapy have recovered to Grade ≤1 according to NCI CTCAE v5.0. * All male subjects and female subjects of childbearing potential must strictly use medically approved contraception throughout the entire study period. All male subjects must also avoid sperm donation during the above period. For women of childbearing potential, the result of serum pregnancy test must be obtained. Women must be non-lactating. * Subject voluntarily enrolls and signs the informed consent form, and agrees to comply with the study treatment plan and visit schedule. Exclusion Criteria: * Hypersensitivity to Rocbrutinib or any study drug in the control group. * Prior treatment with any BTK-targeted therapy (except for intolerance). * Central nervous system (CNS) involvement by lymphoma. * History of other malignancy (except MCL) within the past 2 years, excluding radically cured skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, localized squamous cell carcinoma, etc. * History of major cardiovascular events within 6 months prior to randomization. * Presence of any severe and/or uncontrolled systemic disease that, in the investigator's judgment, or have poor cardiac function. * Uncontrolled active bacterial, fungal, or viral systemic infection, or active tuberculosis infection. * Any medical condition that could interfere with the absorption, distribution, metabolism, or excretion (ADME) of the investigational drug or the evaluation of study outcomes.
References
Publications (0)
Data not yet available